Research Progress on Pathogenesis and Treatment of NUT Carcinoma
Jiaxin DU, Xinwei ZHANG
TL;DR
This paper reviews the genetic cause and treatment advances for NUT carcinoma, a rare aggressive cancer linked to a specific gene fusion.
Contribution
The paper provides an updated overview of the BRD4-NUTM1 fusion's role in NUT carcinoma and progress in developing BET inhibitor drugs.
Findings
NUT carcinoma is characterized by NUTM1 gene rearrangements, particularly the BRD4-NUTM1 fusion.
BET inhibitors are being explored as targeted therapies for NUT carcinoma.
Research is focused on understanding the pathogenesis and improving treatment outcomes.
Abstract
中线癌（nuclear protein in testis carcinoma），又称NUT癌，是一种罕见的高度侵袭性恶性肿瘤，最常见于中线器官和肺。NUT癌的特征性遗传学改变是NUT癌家族成员1（NUT midline carcinoma family member 1, NUTM1）基因重排。本文将对其最常见的融合形式溴结构域蛋白4（bromodomaincontaining protein 4, BRD4）-NUTM1融合基因的致病机制以及靶向药物研发的进展进行综述。 Research progress of BET inhibitors
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsProtein Degradation and Inhibitors